CSPC to launch Paxlovid version in China; SEC charges ex-Pfizer employee with insider trading

Pfizer inked a deal with a Chinese pharma to launch a form of its Covid-19 antiviral Paxlovid in China.

The company is working with CSPC Pharmaceutical Group, which is based in Shijiazhuang, China, to produce and launch a local brand of the antiviral, according to a news release. Bloomberg reported that Pfizer also has agreements with Meheco to sell the drug in China and Zhejiang Huahai Pharmaceutical to make and distribute it.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Columbia medical school gets $400 million gift to fund risky basic research

Columbia University announced Thursday that its medical school has received $400 million to fund a new institute for basic biomedical research to fuel future discoveries

August 22, 2024

Families who ate together more often during the pandemic had more positive interactions

A study reveals that increased family dinner frequency during COVID-19 positively impacts mental health and social interactions in children and adults.

October 31, 2024

How an immunological Trojan horse could treat disease

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian

January 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.